Q3145312 (Q3145312): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Edited by the materialized bot - inferring region from the coordinates) |
(Created claim: summary (P836): Antibiotic Resistance (RAM) is one of the 21st century Global Health Challenges. In Europe, the 2020-25 research agenda of RAM is aimed at the compression of acquisition processes (emergency), transmission and persistence of RAM bacteria that allow the implementation of effective intervention strategies. The risk of acquisition and transmission of opportunistic ADR pathogens in hospitals occurs mostly in ICUs and is associated with individual h...) |
||||||||||||||
| Property / summary | |||||||||||||||
Antibiotic Resistance (RAM) is one of the 21st century Global Health Challenges. In Europe, the 2020-25 research agenda of RAM is aimed at the compression of acquisition processes (emergency), transmission and persistence of RAM bacteria that allow the implementation of effective intervention strategies. The risk of acquisition and transmission of opportunistic ADR pathogens in hospitals occurs mostly in ICUs and is associated with individual host characteristics and local external factors (antibiotic and other drug consumption, demographic factors,..I) that determine the structure and function of the intestinal microbiota at the individual level (“resistance/sensitivity to colonisation”) and at the collective level (“colonisation pressure”). The lack of high sensitivity and specificity tools to identify minority and subspecies-level bacterial populations; and the implementation of mostly retrospective hospital infection surveillance and control systems has delayed understanding of these processes. This project proposes an Analysis of the risks of acquisition and transmission of AMR microorganisms, based on the multidepartmental observation of the ecology and evolution of resistomas in a ICU for 6 months (pooling strategies, warning systems) and the clinical study of patients (digital clinical metadata and-prot Zero Resistance). The group resistome will allow the selection of different “risk ADR scenarios” that will be analysed by high-performance “omics” techniques generated by this consortium for (i) the stratification of patients in resistotypes (ResCap-SeqCapEZ), and enterotypes (kin-genomics, 16SRNA) ii) the analysis of the effects of the interventions (genome-resolved metagenomics and metaproteoms), and iii) the identification of biomarkers. The variables generated will feed a computational prediction system i. Project R+D+i multi (English) | |||||||||||||||
| Property / summary: Antibiotic Resistance (RAM) is one of the 21st century Global Health Challenges. In Europe, the 2020-25 research agenda of RAM is aimed at the compression of acquisition processes (emergency), transmission and persistence of RAM bacteria that allow the implementation of effective intervention strategies. The risk of acquisition and transmission of opportunistic ADR pathogens in hospitals occurs mostly in ICUs and is associated with individual host characteristics and local external factors (antibiotic and other drug consumption, demographic factors,..I) that determine the structure and function of the intestinal microbiota at the individual level (“resistance/sensitivity to colonisation”) and at the collective level (“colonisation pressure”). The lack of high sensitivity and specificity tools to identify minority and subspecies-level bacterial populations; and the implementation of mostly retrospective hospital infection surveillance and control systems has delayed understanding of these processes. This project proposes an Analysis of the risks of acquisition and transmission of AMR microorganisms, based on the multidepartmental observation of the ecology and evolution of resistomas in a ICU for 6 months (pooling strategies, warning systems) and the clinical study of patients (digital clinical metadata and-prot Zero Resistance). The group resistome will allow the selection of different “risk ADR scenarios” that will be analysed by high-performance “omics” techniques generated by this consortium for (i) the stratification of patients in resistotypes (ResCap-SeqCapEZ), and enterotypes (kin-genomics, 16SRNA) ii) the analysis of the effects of the interventions (genome-resolved metagenomics and metaproteoms), and iii) the identification of biomarkers. The variables generated will feed a computational prediction system i. Project R+D+i multi (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: Antibiotic Resistance (RAM) is one of the 21st century Global Health Challenges. In Europe, the 2020-25 research agenda of RAM is aimed at the compression of acquisition processes (emergency), transmission and persistence of RAM bacteria that allow the implementation of effective intervention strategies. The risk of acquisition and transmission of opportunistic ADR pathogens in hospitals occurs mostly in ICUs and is associated with individual host characteristics and local external factors (antibiotic and other drug consumption, demographic factors,..I) that determine the structure and function of the intestinal microbiota at the individual level (“resistance/sensitivity to colonisation”) and at the collective level (“colonisation pressure”). The lack of high sensitivity and specificity tools to identify minority and subspecies-level bacterial populations; and the implementation of mostly retrospective hospital infection surveillance and control systems has delayed understanding of these processes. This project proposes an Analysis of the risks of acquisition and transmission of AMR microorganisms, based on the multidepartmental observation of the ecology and evolution of resistomas in a ICU for 6 months (pooling strategies, warning systems) and the clinical study of patients (digital clinical metadata and-prot Zero Resistance). The group resistome will allow the selection of different “risk ADR scenarios” that will be analysed by high-performance “omics” techniques generated by this consortium for (i) the stratification of patients in resistotypes (ResCap-SeqCapEZ), and enterotypes (kin-genomics, 16SRNA) ii) the analysis of the effects of the interventions (genome-resolved metagenomics and metaproteoms), and iii) the identification of biomarkers. The variables generated will feed a computational prediction system i. Project R+D+i multi (English) / qualifier | |||||||||||||||
point in time: 12 October 2021
| |||||||||||||||
Revision as of 13:37, 12 October 2021
Project Q3145312 in Spain
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No label defined |
Project Q3145312 in Spain |
Statements
82,875.0 Euro
0 references
165,750.0 Euro
0 references
50.0 percent
0 references
1 January 2019
0 references
31 March 2022
0 references
FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
0 references
40°25'0.12"N, 3°42'12.89"W
0 references
28079
0 references
La resistencia a antibióticos (RAM) es uno de los Retos de Salud Global del siglo XXI. En Europa, la agenda de investigación 2020-25 de RAM va dirigida a la compresión de los procesos adquisición (emergencia), transmisión y persistencia de bacterias RAM que permitan la implementación de estrategias de intervención eficaces. El riesgo de adquisición y transmisión de patógenos oportunistas RAM en el ámbito hospitalario se produce mayoritariamente en las UCIs y está asociado a las características individuales del hospedador y a los factores externos locales (consumo de antibióticos y otros fármacos, factores demográficos,..I) que determinan la estructura y la función de la microbiota intestinal a nivel individual (“resistencia/sensibilidad a la colonización”) y a nivel colectivo (“presión de colonización”). La falta de herramientas de alta sensibilidad y especificidad para determinar poblaciones bacterianas minoritarias y a nivel de subespecie; y la aplicación de sistemas de vigilancia y control de la infección hospitalaria mayoritariamente retrospectivos ha demorado la comprensión de dichos procesos. Este proyecto plantea un Análisis de los riesgos de adquisición y transmisión de microorganismos RAM, partiendo de la observación multidepartamental de la ecología y evolución de resistomas en una UCI durante 6 meses (pooling strategies, sistemas de alerta) y el estudio clínico de pacientes (metadatos h. clínica digital y-prot Resistencia Cero). El Resistoma de grupo permitirá seleccionar diferentes “escenarios RAM de riesgo” que serán analizados por técnicas “ómicas” de alto rendimiento generadas por este consorcio para i) la estratificación de pacientes en resistotipos (ResCap-SeqCapEZ), y enterotipos (kin-genomics, 16SRNA) ii) el análisis de los efectos de las intervenciones (genome-resolved metagenomics y metaproteómica), y iii) la identificación de biomarcadores. Las variables generadas allimentarán un sistema computacional de predicción i. Proyecto I+D+i multi (Spanish)
0 references
Antibiotic Resistance (RAM) is one of the 21st century Global Health Challenges. In Europe, the 2020-25 research agenda of RAM is aimed at the compression of acquisition processes (emergency), transmission and persistence of RAM bacteria that allow the implementation of effective intervention strategies. The risk of acquisition and transmission of opportunistic ADR pathogens in hospitals occurs mostly in ICUs and is associated with individual host characteristics and local external factors (antibiotic and other drug consumption, demographic factors,..I) that determine the structure and function of the intestinal microbiota at the individual level (“resistance/sensitivity to colonisation”) and at the collective level (“colonisation pressure”). The lack of high sensitivity and specificity tools to identify minority and subspecies-level bacterial populations; and the implementation of mostly retrospective hospital infection surveillance and control systems has delayed understanding of these processes. This project proposes an Analysis of the risks of acquisition and transmission of AMR microorganisms, based on the multidepartmental observation of the ecology and evolution of resistomas in a ICU for 6 months (pooling strategies, warning systems) and the clinical study of patients (digital clinical metadata and-prot Zero Resistance). The group resistome will allow the selection of different “risk ADR scenarios” that will be analysed by high-performance “omics” techniques generated by this consortium for (i) the stratification of patients in resistotypes (ResCap-SeqCapEZ), and enterotypes (kin-genomics, 16SRNA) ii) the analysis of the effects of the interventions (genome-resolved metagenomics and metaproteoms), and iii) the identification of biomarkers. The variables generated will feed a computational prediction system i. Project R+D+i multi (English)
12 October 2021
0 references
Madrid
0 references
Identifiers
PI18_01942
0 references